WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, May 13, 2004

Updated search 5/04

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=AND	
☐	L1	neri.in.	289
☐	L2	L1 and fibronect$	0
☐	L3	fibronect$	6267
☐	L4	domain or region or portion or moiety or moieties or fragment or subfragment or sub-fragment or section or peptide or epitope	2656412
☐	L5	L4 same l3	2763
☐	L6	L5 same (scfv or sc-fv or fv or monoclonal or hybridoma or chimeric or chimera or humanized or construct or antibodies or antibody)	786
☐	L7	L6 and (extra or angiogenesis or tumor or vasculature or extracellular or foetal or ed or edb or ed-b)	759
☐	L8	L6 and (angiogenesis or tumor or vasculature or extracellular or foetal or edb or ed-b)	715
☐	L9	L6 and (angiogenesis or tumor or extracellular or foetal or edb or ed-b)	711
☐	L10	L6 same (extra or angiogenesis or tumor or vasculature or extracellular or foetal or ed or edb or ed-b)	357
☐	L11	L6 same (extra or angiogenesis or tumor or extracellular or foetal or edb or ed-b)	328
☐	L12	L6 same (angiogenesis or tumor or extracellular or foetal or edb or ed-b)	321
☐	L13	L6 same (angiogenesis or tumor or foetal or edb or ed-b)	129
☐	L14	L3.clm.	726
☐	L15	L4.clm.	1441895
☐	L16	L15 and l14	346
☐	L17	L16 and (scfv or sc-fv or fv or monoclonal or hybridoma or chimeric or chimera or humanized or construct or antibodies or antibody or singlechain or single-chain or (single near chain)).clm.	102
☐	L18	(angiogenesis or tumor or vasculature or extracellular or foetal or edb or ed-b).clm.	9892
☐	L19	L18 and l17	39

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 39 of 39 returned.

☐ 1. 6696276. 13 Jan 03; 24 Feb 04. Vasopermeability-enhancing conjugates. Epstein; Alan L., et al. 435/69.6; 424/178.1 530/382. C12P021/04 A61K039/44 C07K017/00.

☐ 2. 6689165. 30 Mar 01; 10 Feb 04. Surface modifications for enhanced epithelialization. Jacob; Jean T., et al. 623/5.16; 623/5.11. A61F002/14.

☐ 3. 6666893. 28 Mar 01; 23 Dec 03. Absorbable tissue expander. Burg; Karen J. L., et al. 623/23.75; 623/23.64 623/23.67 623/23.76 623/8. A61F002/02.

☐ 4. 6660842. 19 Sep 00; 09 Dec 03. Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen. Sallberg; Matti. 530/350; 435/7.1 530/324 530/325 530/326 530/331 530/382 530/807. C07K001/00.

☐ 5. 6605751. 29 Sep 00; 12 Aug 03. Silver-containing compositions, devices and methods for making. Gibbins; Bruce L., et al. 602/41; 602/43 602/48. A61F013/00.

☐ 6. 6582391. 02 Jul 02; 24 Jun 03. Hybrid matrix implants and explants. Mineau-Hanschke; Rochelle. 604/19; 424/93.1 424/93.21 435/289.1 435/297.1 435/325 435/382 604/5.01 604/890.1. A61N001/30 A61M037/00 A61K009/22 A61K048/00 C12N005/00.

☐ 7. 6566074. 15 Mar 00; 20 May 03. Methods of modulating cell attachment and migration. Goetinck; Paul F.. 435/7.1; 435/252.3 435/69.1 435/69.7 530/395. G01N033/53 C12P021/06 C12N001/20.

☐ 8. 6524823. 27 Jul 01; 25 Feb 03. Vasopermeability-enhancing conjugates. Epstein; Alan L., et al. 435/69.6; 424/155.1 424/176.1 424/178.1 424/180.1 424/183.1 435/70.21 530/350 530/380 530/382 530/387.1 530/388.1 530/391.1. C12P021/04 A61K039/395 A61K035/14 C07K001/00 C07K016/00.

☐ 9. 6428579. 29 Dec 99; 06 Aug 02. Implantable prosthetic devices coated with bioactive molecules. Valentini; Robert F.. 623/23.76; 427/2.13 427/2.24 606/76 623/23.74. A61F002/36.

☐ 10. 6406693. 12 Jul 99; 18 Jun 02. Cancer treatment methods using antibodies to aminophospholipids. Thorpe; Philip E., et al. 424/130.1; 424/132.1 424/133.1 424/135.1 424/138.1 424/141.1 424/152.1 424/184.1 435/6 530/387.1. A61K039/395 C07K016/00 C07K016/28 C07K016/30 C12Q001/68.

☐ 11. 6379667. 03 Aug 99; 30 Apr 02. Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction. Khaw; Peng Tee, et al. 424/146.1; 424/141.1 514/575. A61K039/395 A61K013/19.

☐ 12. 6310177. 22 Feb 00; 30 Oct 01. Compounds and methods for modulating tissue permeability. Blaschuk; Orest W., et al. 530/317; 206/569 424/185.1. A61K038/00 C07K005/00 C07K007/00 C12N005/00.

☐ 13. 6265229. 04 Nov 96; 24 Jul 01. Method and device for detection of specific target cells in

specialized or mixed cell populations and solutions containing mixed cell populations. Fodstad; .O slashed.ystein, et al. 436/526; 422/101 435/33 435/395 435/7.2 435/7.21 435/7.23 435/7.24 436/518 436/525 436/809. G01N033/553 B01L011/00.

☐ 14. 6218187. 11 Mar 99; 17 Apr 01. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells. Finer; Mitchell H., et al. 435/457; 435/320.1 435/325 435/368 435/369 435/370 435/371 435/372 435/372.2 435/372.3 435/373 435/455 435/456 435/462 435/463 530/388.2. C12N015/867 C12N015/63 C12N005/10.

☐ 15. 6210655. 18 Jun 97; 03 Apr 01. Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging. Stein; Stanley. 424/9.34; 424/9.3 600/420. A61B005/055.

☐ 16. 6133030. 03 Oct 97; 17 Oct 00. Co-cultivation of cells in a micropatterned configuration. Bhatia; Sangeeta, et al. 435/373; 435/177 435/289.1 435/305.1 435/309.1 435/395 435/402. C12N005/00 C12N011/02.

☐ 17. 6093399. 07 Jun 95; 25 Jul 00. Methods and compositions for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/182.1; 424/178.1 424/179.1 424/180.1 530/387.1 530/387.3 530/387.7 530/387.9 530/388.1 530/388.22 530/388.85 530/391.7 530/391.9. A61K039/395.

☐ 18. 6093398. 19 Nov 96; 25 Jul 00. Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction. Khaw; Peng Tee, et al. 424/146.1; 424/130.1 424/141.1 514/323 514/419 514/542 514/562 514/563 514/575. A61K039/395 A61K031/235.

☐ 19. 6054142. 01 Aug 96; 25 Apr 00. Biocompatible devices with foam scaffolds. Li; Rebecca, et al. 424/426; 424/422 424/423 424/433 424/486 424/550 424/551 424/556 424/557 424/558 424/559 424/561 424/562 424/563 424/565 424/568 424/569 424/570 424/571 424/572 424/573 424/574 424/577 424/578 424/579 424/580 424/85.1 424/93.7 435/177 435/180 435/ 182 523/112 523/113 523/122 524/17 524/21 524/9. A61K009/00.

☐ 20. 6008319. 23 Dec 96; 28 Dec 99. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof. Epstein; Alan L., et al. 530/324; 435/320.1 435/325 530/351 530/387.1 530/387.3 530/388.1 530/388.15 530/402. C07K014/55 C07K016/18 C12N005/10.

☐ 21. 6007817. 10 Apr 95; 28 Dec 99. Vasopermeability enhancing immunoconjugates. Epstein; Alan L., et al. 424/178.1; 424/155.1 424/174.1 424/180.1 424/183.1 435/69.6 435/70.21 530/350 530/380 530/382 530/387.1 530/388.1 530/388.8 530/388.85 530/391.1 530/391.3. A61K039/395 C12P021/04 C12N015/00 C07K001/00.

☐ 22. 6004555. 07 Jun 95; 21 Dec 99. Methods for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/181.1; 424/178.1 424/180.1 435/7.23 530/381 530/382 530/383 530/384 530/391.7. A61K039/395 A61K035/14 C07K016/00 G01N033/574.

☐ 23. 5989850. 26 Aug 98; 23 Nov 99. Methods of testing cancer cells and anticancer drugs. Livant; Donna L.. 435/29; 435/4 435/7.1 435/7.21. C12Q001/02 C12Q001/00.

☐ 24. 5985278. 19 Dec 95; 16 Nov 99. Anti-.alpha.V-integrin monoclonal antibody. Mitjans; Francesc, et al. 424/143.1; 424/130.1 424/133.1 424/138.1 424/141.1 424/152.1 424/172.1 435/326 435/330 435/332 435/346 435/452 435/70.21 530/387.1 530/387.3 530/387.7 530/388.2 530/388.22 530/388.8 536/23.53. A61K039/395 C07K016/28 C12N015/13 C12N005/12.

☐ 25. 5952224. 20 Aug 97; 14 Sep 99. Selection of cells having increased cell adhesion properties. Pierschbacher; Michael D., et al. 435/325; 435/375 435/377 530/350 530/356. C12N005/00.

☐ 26. 5922302. 15 May 95; 13 Jul 99. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates. Goldenberg; David Milton, et al. 424/1.41; 424/1.45 424/9.2 424/9.3 424/9.34 530/367 530/391.3 530/400 530/402 548/303.7. A61K051/00 C07K016/00.

☐ 27. 5877289. 07 Jun 95; 02 Mar 99. Tissue factor compositions and ligands for the specific coagulation of vasculature. Thorpe; Philip E., et al. 530/387.1; 530/381 530/387.3 530/387.7 530/387.9 530/388.1 530/388.22 530/388.85 530/391.7 530/391.9. A61K039/395.

☐ 28. 5874164. 07 Jun 95; 23 Feb 99. Barrier webs having bioactive surfaces. Caldwell; J. Michael. 428/306.6; 424/278.1 424/443 424/499 428/308.4 428/317.1 428/422 428/447 442/76 442/79 442/82. B32B003/06.

☐ 29. 5874099. 24 May 95; 23 Feb 99. Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 30. 5866113. 07 Mar 97; 02 Feb 99. Medical device with biomolecule-coated surface graft matrix. Hendriks; Marc, et al. 424/78.17; 424/486 424/487 424/78.18 427/2.24 427/2.25 427/2.28 427/2.3 525/78 530/815 530/816. A61K031/765 A61K031/78 A61K027/00 C08L033/02.

☐ 31. 5834001. 24 May 95; 10 Nov 98. Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 32. 5800829. 24 May 95; 01 Sep 98. Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 33. 5800828. 10 Jan 94; 01 Sep 98. Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490 514/814 514/866. A61K009/50 A61K009/14.

☐ 34. 5798113. 24 May 95; 25 Aug 98. Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490 514/814 514/866. A61K009/50 A61K009/14.

☐ 35. 5759205. 20 Jan 95; 02 Jun 98. Negatively charged polymeric electret implant. Valentini; Robert F.. 433/173; 433/201.1 623/23.61 623/23.72. A61F002/28.

☐ 36. 5700681. 20 Dec 94; 23 Dec 97. Selection of cells having increased cell adhesion properties. Pierschbacher; Michael D., et al. 435/377; 435/378 530/350 530/356. C12N005/06 C07K014/00.

☐ 37. 5420012. 23 Oct 92; 30 May 95. Method for the detection of reactive conditions. Partanen; Paul, et al. 435/7.23; 435/7.92 435/7.93 436/518 436/531 436/813 436/815. G01N033/574.

☐ 38. 5188959. 18 May 90; 23 Feb 93. Extracellular matrix protein adherent T cells. Haberman;

Allan B.. 435/6; 435/332 435/373 435/385 435/4 435/402. C12N005/00 C12N005/08 C12Q001/04.

☐ 39. 4894326. 09 Apr 86; 16 Jan 90. Monoclonal antibody defining oncofetal structure of fibronectin. Matsuura; Hidemitsu, et al. 435/7.21; 435/337 435/344.1 435/7.23 435/7.7 435/7.71 435/810 435/948 435/975 436/518 436/536 436/547 436/548 436/813 530/388.2 530/388.25 530/388.85 530/391.3 530/809. C07K015/14 G01N033/574 G01N033/577.

Generate Collection Print

Terms	Documents
L18 and L17	39

Prev Page Next Page Go to Doc#

First Hit Fwd Refs

L19: Entry 1 of 39 File: USPT Feb 24, 2004

US-PAT-NO: 6696276
DOCUMENT-IDENTIFIER: US 6696276 B2

TITLE: Vasopermeability-enhancing conjugates

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Epstein; Alan L.	La Canada	CA		
Glovsky; Michael	Los Angeles	CA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
University of Southern California	Los Angeles	CA			02

APPL-NO: 10/ 342426 [PALM]
DATE FILED: January 13, 2003

PARENT-CASE:
RELATION TO RELATED APPLICATION This application is a continuation of U.S. patent application Ser. No. 09/916,883, now U.S. Pat. No. 6,524,823, filed on Jul. 27, 2001, which is a continuation of U.S. patent application Ser. No. 09/382,359, now U.S. Pat. No. 6,274,343, filed on Aug. 24, 1999, which is a continuation of U.S. patent application Ser. No. 08/419,645, now U.S. Pat. No. 6,007,817, filed on Apr. 10, 1995, which is a continuation of U.S. patent application Ser. No. 08/127,988, filed on Sep. 27, 1993, abandoned, which is a continuation of U.S. patent application Ser. No. 07/964,517, filed on Oct. 21, 1992, abandoned, which is a continuation of U.S. patent application Ser. No. 07/417,782, filed on Oct. 4, 1989, abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 07/255,513, filed on Oct. 11, 1988, abandoned. Each of the above mentioned patents is incorporated by reference herein, in its entirety.

INT-CL: [07] C12 P 21/04, A61 K 39/44, C07 K 17/00

US-CL-ISSUED: 435/69.6; 424/178.1, 530/382
US-CL-CURRENT: 435/69.6; 424/178.1, 530/382

FIELD-OF-SEARCH: 435/69.6, 424/178.1, 530/382

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected Search ALL Clear

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
☐	4101380	July 1978	Rubinstein et al.	
☐	4110432	August 1978	Wilkinson et al.	
☐	4671958	June 1987	Rodwell et al.	
☐	4673573	June 1987	Ferres et al.	
☐	4724212	February 1988	Epstein	
☐	4724213	February 1988	Epstein	
☐	4753894	June 1988	Frankel et al.	
☐	4843147	June 1989	Levy et al.	
☐	4863726	September 1989	Stevens et al.	
☐	4894227	January 1990	Stevens et al.	
☐	4975278	December 1990	Senter et al.	
☐	5061626	October 1991	Baldo et al.	
☐	5241078	August 1993	Moreland et al.	
☐	6007817	December 1999	Epstein et al.	424/178.1
☐	6274343	August 2001	Epstein et al.	435/69.6
☐	6524823	February 2003	Epstein et al.	435/69.6

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
8603938	January 1986	WO	

OTHER PUBLICATIONS

Antoni, G. et al. J. of Immunol. 137:3201-04 1986.
Bindon et al. Brit. J. Cancer 47:123-133 1983.
Biochem, Biophys. Res. Comm., 155:1139-1144 (1988).
Birnbaum et al. J. Medicinal Chem. 25(5):492-94 1982.
Bomber et al., "Propanolol Hydrochloride Enhancement of Tumor Perfusion and Uptake of Gallium-67 in a Mouse Sarcoma," J. Nucl. Med. 27:243-245, Feb. 1986.
Bomber, P. et al. J. Nucl. Med. 27:243-45 1986.
Braquet, P. and Rola-Pleszezynski, M. Immunol. Today 8(11):345-52 1987.
Burger, et al., Chem. Abst. 109: 511, Abst. No. 127053u (1988).
Carlsson, J. et al. Biochem J. 173:723-737 1978.
Cater et al., "Inflammatory Changes in Tumour Vessels after Systemic 5-Hydroxytrptamine, Bradykinin, Kallikrein, or Lysolecithin," in Tumour Vascularity and Inflammatory Mediators (1967).
Cellular Immunology, 81:169-174 (1983).
Chan, et al. J. of Hypertension 4(6):741-746 1986.
De Nardo, S. et al. Nucl. Med. Biol. 13:303-10 1986.
Dillman, R.O., Annals of Internal Medicine 111:592-603, 1989.
Dvorak et al., Am J. Path, 133:95-109 (1988).
Eisenthal, et al., Cancer Res. 48 (24) Part 1: 7140-45 (1988).
Eisenthal, et al., Chem. Abst. 109: 527, Abst. No. 90913w (1988).
Epenetos et al. Cancer Res. 46:3183-91 1986.
Epstein, A. et al. Malignant Lymphomas and Hodgkins Disease: Expla. and Th'ptc.

Advcs. Martinus Nijoff Publ. Co. Boston 1985 pp. 569-577.
Erspamer, V. TINS Nov. 1981 pp. 267-269.
Fairman, R. et al. Cancer Res. 47:3528-32 1987.
Flannery et al., Eur. J. Cancer Clin., Oncol., 20:514-517 (1985).
Flannery, G. et al. Eur. J. Cancer Clin. Oncol. 20(6):791-798 1984.
Foon et al. Blood 64:1085-1093 1984.
Ghose, T. et al. J. Natl. Cancer Inst. 58:845-52 1977.
Glovsky, M. et al. J. of the Reticuloendthelial Society 33:401-13 1983.
Goodfriend, T. et al. Science 144:1344-46 1964.
Hagermark, O. et al. J. or Invest. Dermatology 71:233-235 1978.
Hirai, Y. et al. Chem. Pharm. Bull. 27(8):1942-44 1979.
Hird et al, in Genes and Cancer, Corney et al, Eds., Wiley & Sons, pp. 183-189, 1990.
Hugli, T. and Erickson, B. PNAS-USA 74:1826-30 1977.
Hurwitz, E. et al. Cancer Res. 35:1175-81 1975.
Kaelin, N. et al. Cancer Res. 44:896-99 1984.
Kampschmidt, R. J. Leukocyte Biol. 36:341-55 1984.
Kawase, et al., Cancer Res. 48(5): 1173-79 (1988).
Kitao, T. and Hattori, K. Nature 265:81-82 1977.
Kohler and Milstein Nature 256:495 1975.
Lembeck, F. and Halzer, P. Naunyn-Schmeideberg's Arch. Pharmacol. 310:175-83 1979.
Levy and Miller, Fed Proc. 42:2650-56 1983.
Lowder et al. Blood 69:199-210 1987.
McFarlane, A. Biochem. J. 62:135-143 1956.
Nagata, S. et al. Int. Archs. Allergy Appl. Immun 82:4-9 1987.
Obrist et al., in Int. J. Immunopharm, 5:307-314 (1983).
Obrist, et al., Blut 53:251, 1986, Abstract No. 243.
Obrist, et al., Cellular Immunology 81:169-174, 1983.
Obrist, R. and Sandburg, A. Cellular Imun. 81:169-74 1983.
Obrist, R. et al. Blut 53:251 1986.
Okano, Y. et al. Fed. Europ. Biochem. Soc. 185(2):363-66 1985.
Osband et al., Immunology Today 11(6):193-195, 1990.
Pelham et al., Cancer Immunol. Immunother., 15:210-216 (1983).
Philip, et al., Nature 323: 86-89 (1986).
Philip, R. and Epstein, L. Nature 323:86-89 1986.
Porter, R. Biochem J. 73:119 1959.
Rosenstein et al. J. of Immunol. 1735-42 1986.
Sands et al. Cancer Res. 48:186-93 1988.
Sands et al., "Correlation of Vascular Permeability and Blood Flow with Monoclonal Antibody Uptake by Human Clouser and Renal Cell Xenografts," Cancer Research 48:188-48:188-193, Jan. 1, 1988.
Sands, et al., Cancer Res. 48: 188-193 (1988).
Sears, et al. Cancer Res. 45:5910-5913 1985.
Seon, B. Cancer Res. 44:259-64 1984.
Serafin, W. and Austin, K. New England J. of Med., Jul. 2, 1987 pp. 30-34.
Shen, W.C., Ryser, H. Biochem. Biophys. Res. Comm 102(3):1048-1054 1981.
Sherwood, E. et al. J. of Biological Response Modifiers 7:185-98 1988.
Sherwood, et al., J. Biol. Resp. Modif. 7(2): 185-198 (1988).
Smyth, et al., JNCI 76(3): 503-510 (1986).
Smyth, M. et al. J. Natl. Cancer Inst. 76(3):503-10 1986.
Talmadge et al. Cancer Res. 47:2563-70 1987.
Taniguchi, T. Nature 302:305-10 1983.
Thomlinson, P. and Gray, L. British J. Cancer 9:539-549 1955.
Turnbull, L. et al. Immunology 32:57-63 1977.
Vogel et al., Haematology and Blood Transfusion, 29:514-517 (1985).
Vogel, "Antibody Conjugates without Inherent Toxicity: The Targeting of Cobra Venom Factor and other Biological Response Modifiers" in Immunoconjugates (C. Vogel, ed.), ed.), pp. 170-188 (1987).
Vogel, C. and Muller-Eberhard, H. PNAS-USA 78(12):7707-11.
Vogel, C. et al. Hematology and Blood Transfusion Modern Trends in Human Leukemia VI

VI 29:514-17 Neth et al. eds Berlin 1985.
Wahl et al. J. Nucl. Med. 24:315-325 1983.
Waldmann, T.A., Science 252:1657-1662, Jun. 21, 1991.
Wilbanks et al. Cancer 48:1768-75 1981.
Ziltener, H.J. et al. J. Immunol 138:1099-1104 1987.

ART-UNIT: 1648

PRIMARY-EXAMINER: Park; Hankyel T.

ATTY-AGENT-FIRM: Knobbe Martens Olson & Bear LLP

ABSTRACT:

Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.

18 Claims, 4 Drawing figures

First Hit Fwd Refs

L19: Entry 15 of 39 File: USPT Apr 3, 2001

DOCUMENT-IDENTIFIER: US 6210655 B1
TITLE: Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging

CLAIMS:

2. The magnetic resonance imaging reagent according to claim 1, wherein the site-specific targeting group is an organic compound, peptide, or protein selected from the group consisting of polyclonal antibodies, monoclonal antibodies, single chain antibodies, and Fab fragments.

3. The magnetic resonance imaging reagent according to claim 2, wherein the site-specific targeting group is selected from the group consisting of blood clot targeting groups, .beta.-amyloid plaque targeting groups of Alzheimer's disease, Congo red, and tumor-specific antigen targeting groups.

4. The magnetic resonance imaging reagent according to claim 2, wherein the site-specific targeting group is selected from the group consisting of antifibrin monoclonal antibodies, fibrin-binding domain fragment of fibronectin, activated-platelet binding protein fragment, and inactivated tissue plasminogen activator.

7. The magnetic resonance imaging reagent according to claim 3, wherein the site-specific targeting group is a .beta.-amyloid peptide of Alzheimer's disease.

9. The method according to claim 8, wherein the site-specific targeting group is an organic compound, peptide, or protein selected from the group consisting of polyclonal antibodies, monoclonal antibodies, single chain antibodies, and Fab fragments.

10. The method according to claim 9, wherein the site-specific targeting group is selected from the group consisting of blood clot targeting groups, .beta.-amyloid plaque targeting groups of Alzheimer's disease, Congo red, and tumor-specific antigen targeting groups.

11. The method according to claim 9, wherein the site-specific targeting group is selected from the group consisting of antifibrin monoclonal antibodies, fibrin-binding domain fragment of fibronectin, activated-platelet binding protein fragment, and inactivated tissue plasminogen activator.

14. The method according to claim 10, wherein the site-specific targeting group is a .beta.-amyloid peptide of Alzheimer's disease.

Generate Collection Print

Search Results - Record(s) 1 through 39 of 39 returned.

☐ 1. 6696276. 13 Jan 03; 24 Feb 04. Vasopermeability-enhancing conjugates. Epstein; Alan L., et al. 435/69.6; 424/178.1 530/382. C12P021/04 A61K039/44 C07K017/00.

☐ 2. 6689165. 30 Mar 01; 10 Feb 04. Surface modifications for enhanced epithelialization. Jacob; Jean T., et al. 623/5.16; 623/5.11. A61F002/14.

☐ 3. 6666893. 28 Mar 01; 23 Dec 03. Absorbable tissue expander. Burg; Karen J. L., et al. 623/23.75; 623/23.64 623/23.67 623/23.76 623/8. A61F002/02.

☐ 4. 6660842. 19 Sep 00; 09 Dec 03. Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen. Sallberg; Matti. 530/350; 435/7.1 530/324 530/325 530/326 530/331 530/382 530/807. C07K001/00.

☐ 5. 6605751. 29 Sep 00; 12 Aug 03. Silver-containing compositions, devices and methods for making. Gibbins; Bruce L., et al. 602/41; 602/43 602/48. A61F013/00.

☐ 6. 6582391. 02 Jul 02; 24 Jun 03. Hybrid matrix implants and explants. Mineau-Hanschke; Rochelle. 604/19; 424/93.1 424/93.21 435/289.1 435/297.1 435/325 435/382 604/5.01 604/890.1. A61N001/30 A61M037/00 A61K009/22 A61K048/00 C12N005/00.

☐ 7. 6566074. 15 Mar 00; 20 May 03. Methods of modulating cell attachment and migration. Goetinck; Paul F.. 435/7.1; 435/252.3 435/69.1 435/69.7 530/395. G01N033/53 C12P021/06 C12N001/20.

☐ 8. 6524823. 27 Jul 01; 25 Feb 03. Vasopermeability-enhancing conjugates. Epstein; Alan L., et al. 435/69.6; 424/155.1 424/176.1 424/178.1 424/180.1 424/183.1 435/70.21 530/350 530/380 530/382 530/387.1 530/388.1 530/391.1. C12P021/04 A61K039/395 A61K035/14 C07K001/00 C07K016/00.

☐ 9. 6428579. 29 Dec 99; 06 Aug 02. Implantable prosthetic devices coated with bioactive molecules. Valentini; Robert F.. 623/23.76; 427/2.13 427/2.24 606/76 623/23.74. A61F002/36.

☐ 10. 6406693. 12 Jul 99; 18 Jun 02. Cancer treatment methods using antibodies to aminophospholipids. Thorpe; Philip E., et al. 424/130.1; 424/132.1 424/133.1 424/135.1 424/138.1 424/141.1 424/152.1 424/184.1 435/6 530/387.1. A61K039/395 C07K016/00 C07K016/28 C07K016/30 C12Q001/68.

☐ 11. 6379667. 03 Aug 99; 30 Apr 02. Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction. Khaw; Peng Tee, et al. 424/146.1; 424/141.1 514/575. A61K039/395 A61K013/19.

☐ 12. 6310177. 22 Feb 00; 30 Oct 01. Compounds and methods for modulating tissue permeability. Blaschuk; Orest W., et al. 530/317; 206/569 424/185.1. A61K038/00 C07K005/00 C07K007/00 C12N005/00.

☐ 13. 6265229. 04 Nov 96; 24 Jul 01. Method and device for detection of specific target cells in

specialized or mixed cell populations and solutions containing mixed cell populations. Fodstad; .O slashed.ystein, et al. 436/526; 422/101 435/33 435/395 435/7.2 435/7.21 435/7.23 435/7.24 436/518 436/525 436/809. G01N033/553 B01L011/00.

☐ 14. 6218187. 11 Mar 99; 17 Apr 01. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells. Finer; Mitchell H., et al. 435/457; 435/320.1 435/325 435/368 435/369 435/370 435/371 435/372 435/372.2 435/372.3 435/373 435/455 435/456 435/462 435/463 530/388.2. C12N015/867 C12N015/63 C12N005/10.

☐ 15. 6210655. 18 Jun 97; 03 Apr 01. Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging. Stein; Stanley. 424/9.34; 424/9.3 600/420. A61B005/055.

☐ 16. 6133030. 03 Oct 97; 17 Oct 00. Co-cultivation of cells in a micropatterned configuration. Bhatia; Sangeeta, et al. 435/373; 435/177 435/289.1 435/305.1 435/309.1 435/395 435/402. C12N005/00 C12N011/02.

☐ 17. 6093399. 07 Jun 95; 25 Jul 00. Methods and compositions for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/182.1; 424/178.1 424/179.1 424/180.1 530/387.1 530/387.3 530/387.7 530/387.9 530/388.1 530/388.22 530/388.85 530/391.7 530/391.9. A61K039/395.

☐ 18. 6093398. 19 Nov 96; 25 Jul 00. Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction. Khaw; Peng Tee, et al. 424/146.1; 424/130.1 424/141.1 514/323 514/419 514/542 514/562 514/563 514/575. A61K039/395 A61K031/235.

☐ 19. 6054142. 01 Aug 96; 25 Apr 00. Biocompatible devices with foam scaffolds. Li; Rebecca, et al. 424/426; 424/422 424/423 424/433 424/486 424/550 424/551 424/556 424/557 424/558 424/559 424/561 424/562 424/563 424/565 424/568 424/569 424/570 424/571 424/572 424/573 424/574 424/577 424/578 424/579 424/580 424/85.1 424/93.7 435/177 435/180 435/ 182 523/112 523/113 523/122 524/17 524/21 524/9. A61K009/00.

☐ 20. 6008319. 23 Dec 96; 28 Dec 99. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof. Epstein; Alan L., et al. 530/324; 435/320.1 435/325 530/351 530/387.1 530/387.3 530/388.1 530/388.15 530/402. C07K014/55 C07K016/18 C12N005/10.

☐ 21. 6007817. 10 Apr 95; 28 Dec 99. Vasopermeability enhancing immunoconjugates. Epstein; Alan L., et al. 424/178.1; 424/155.1 424/174.1 424/180.1 424/183.1 435/69.6 435/70.21 530/350 530/380 530/382 530/387.1 530/388.1 530/388.8 530/388.85 530/391.1 530/391.3. A61K039/395 C12P021/04 C12N015/00 C07K001/00.

☐ 22. 6004555. 07 Jun 95; 21 Dec 99. Methods for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/181.1; 424/178.1 424/180.1 435/7.23 530/381 530/382 530/383 530/384 530/391.7. A61K039/395 A61K035/14 C07K016/00 G01N033/574.

☐ 23. 5989850. 26 Aug 98; 23 Nov 99. Methods of testing cancer cells and anticancer drugs. Livant; Donna L.. 435/29; 435/4 435/7.1 435/7.21. C12Q001/02 C12Q001/00.

☐ 24. 5985278. 19 Dec 95; 16 Nov 99. Anti-.alpha.V-integrin monoclonal antibody. Mitjans; Francesc, et al. 424/143.1; 424/130.1 424/133.1 424/138.1 424/141.1 424/152.1 424/172.1 435/326 435/330 435/332 435/346 435/452 435/70.21 530/387.1 530/387.3 530/387.7 530/388.2 530/388.22 530/388.8 536/23.53. A61K039/395 C07K016/28 C12N015/13 C12N005/12.

☐ 25. 5952224. 20 Aug 97; 14 Sep 99. Selection of cells having increased cell adhesion properties. Pierschbacher; Michael D., et al. 435/325; 435/375 435/377 530/350 530/356. C12N005/00.

☐ 26. 5922302. 15 May 95; 13 Jul 99. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates. Goldenberg; David Milton, et al. 424/1.41; 424/1.45 424/9.2 424/9.3 424/9.34 530/367 530/391.3 530/400 530/402 548/303.7. A61K051/00 C07K016/00.

☐ 27. 5877289. 07 Jun 95; 02 Mar 99. Tissue factor compositions and ligands for the specific coagulation of vasculature. Thorpe; Philip E., et al. 530/387.1; 530/381 530/387.3 530/387.7 530/387.9 530/388.1 530/388.22 530/388.85 530/391.7 530/391.9. A61K039/395.

☐ 28. 5874164. 07 Jun 95; 23 Feb 99. Barrier webs having bioactive surfaces. Caldwell; J. Michael. 428/306.6; 424/278.1 424/443 424/499 428/308.4 428/317.1 428/422 428/447 442/76 442/79 442/82. B32B003/06.

☐ 29. 5874099. 24 May 95; 23 Feb 99. Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 30. 5866113. 07 Mar 97; 02 Feb 99. Medical device with biomolecule-coated surface graft matrix. Hendriks; Marc, et al. 424/78.17; 424/486 424/487 424/78.18 427/2.24 427/2.25 427/2.28 427/2.3 525/78 530/815 530/816. A61K031/765 A61K031/78 A61K027/00 C08L033/02.

☐ 31. 5834001. 24 May 95; 10 Nov 98. Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 32. 5800829. 24 May 95; 01 Sep 98. Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490. A61K009/50 A61K009/14.

☐ 33. 5800828. 10 Jan 94; 01 Sep 98. Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490 514/814 514/866. A61K009/50 A61K009/14.

☐ 34. 5798113. 24 May 95; 25 Aug 98. Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products. Dionne; Keith E., et al. 424/422; 424/423 424/424 424/426 424/427 424/430 424/434 424/437 424/489 424/490 514/814 514/866. A61K009/50 A61K009/14.

☐ 35. 5759205. 20 Jan 95; 02 Jun 98. Negatively charged polymeric electret implant. Valentini; Robert F.. 433/173; 433/201.1 623/23.61 623/23.72. A61F002/28.

☐ 36. 5700681. 20 Dec 94; 23 Dec 97. Selection of cells having increased cell adhesion properties. Pierschbacher; Michael D., et al. 435/377; 435/378 530/350 530/356. C12N005/06 C07K014/00.

☐ 37. 5420012. 23 Oct 92; 30 May 95. Method for the detection of reactive conditions. Partanen; Paul, et al. 435/7.23; 435/7.92 435/7.93 436/518 436/531 436/813 436/815. G01N033/574.

☐ 38. 5188959. 18 May 90; 23 Feb 93. Extracellular matrix protein adherent T cells. Haberman;

Allan B.. 435/6; 435/332 435/373 435/385 435/4 435/402. C12N005/00 C12N005/08 C12Q001/04.

☐ 39. 4894326. 09 Apr 86; 16 Jan 90. Monoclonal antibody defining oncofetal structure of fibronectin. Matsuura; Hidemitsu, et al. 435/7.21; 435/337 435/344.1 435/7.23 435/7.7 435/7.71 435/810 435/948 435/975 436/518 436/536 436/547 436/548 436/813 530/388.2 530/388.25 530/388.85 530/391.3 530/809. C07K015/14 G01N033/574 G01N033/577.

Generate Collection Print

Terms	Documents
L18 and L17	39

Prev Page Next Page Go to Doc#

First Hit Fwd Refs

L19: Entry 17 of 39 File: USPT Jul 25, 2000

US-PAT-NO: 6093399
DOCUMENT-IDENTIFIER: US 6093399 A
**** See image for Certificate of Correction ****

TITLE: Methods and compositions for the specific coagulation of vasculature

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Edgington; Thomas S.	La Jolla	CA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Board of Regents, The University of Texas System	Austin	TX			02
The Scripps Research Institute	La Jolla	CA			02

APPL-NO: 08/ 482369 [PALM]
DATE FILED: June 7, 1995

PARENT-CASE:
The present application is a continuation-in-part of U.S. patent application Ser. No. 08/273,567 (ABN), filed Jul. 11, 1994; which is a continuation-in-part of U.S. patent application Ser. No. 08/205,330, filed Mar. 2, 1994; which is a continuation-in-part of U.S. Ser. No. 07/846,349 (ABN), filed Mar. 5, 1992. The entire text and figures of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer.

INT-CL: [07] A61 K 39/395

US-CL-ISSUED: 424/182; 530/387.3, 530/387.7, 530/387.9, 530/387.1, 530/388.1, 530/388.22, 530/388.85, 530/391.7, 530/391.9, 424/178.1, 424/180.1, 424/179.1
US-CL-CURRENT: 424/182.1; 424/178.1, 424/179.1, 424/180.1, 530/387.1, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.22, 530/388.85, 530/391.7, 530/391.9

FIELD-OF-SEARCH: 424/182.1, 424/178.1, 424/179.1, 424/180.1, 530/387.1, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.22, 530/388.85, 530/391.7, 530/391.9

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

☐	4456550	June 1984	Dvorak et al.	260/112R
☐	4472509	September 1984	Gansow et al.	
☐	4536387	August 1985	Sakamoto et al.	424/14
☐	4785077	November 1988	Kornbluth et al.	530/351
☐	4975369	December 1990	Beavers et al.	435/69.1
☐	5017556	May 1991	O'Brien et al.	514/2
☐	5021236	June 1991	Gries et al.	
☐	5081034	January 1992	Bevilacqua et al.	
☐	5110730	May 1992	Edgington et al.	435/69.6
☐	5183756	February 1993	Schlom	435/240.27
☐	5202253	April 1993	Esmon et al.	435/240.27
☐	5223427	June 1993	Edgington et al.	435/240.27
☐	5242813	September 1993	Pastan et al.	435/70.21
☐	5298599	March 1994	Rezaie et al.	530/350
☐	5314695	May 1994	Brown	424/450
☐	5342757	August 1994	Garin-Chesa et al.	435/7.21
☐	5346991	September 1994	Roy et al.	530/350
☐	5374617	December 1994	Morrissey et al.	514/8
☐	5399346	March 1995	Anderson et al.	424/93.21
☐	5403713	April 1995	Bevilacqua et al.	435/7.1
☐	5437864	August 1995	Edgington et al.	424/145.1
☐	5504064	April 1996	Morrissey et al.	514/8
☐	5504067	April 1996	Morrissey et al.	514/8
☐	5589173	December 1996	O'Brien et al.	424/145.1
☐	5589363	December 1996	Roy et al.	435/69.6
☐	5632991	May 1997	Gimbrone, Jr.	424/178.1
☐	5726147	March 1998	Ruf et al.	514/2
☐	5739101	April 1998	Roy et al.	514/2

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
WO 81/01145	April 1981	WO	
WO 90/03801	April 1990	WO	
WO 90/05539	May 1990	WO	
WO 90/12585	November 1990	WO	
WO 90/13300	November 1990	WO	
WO 92/12729	August 1992	WO	
WO 92/16558	October 1992	WO	

WO 92/19646	November 1992	WO
WO 93/08210	April 1993	WO
WO 93/08473	April 1993	WO
WO 93/09803	May 1993	WO
WO 93/17715	September 1993	WO
WO 93/23074	November 1993	WO
WO 94/05328	March 1994	WO
WO 94/07515	April 1994	WO
WO 94/11499	May 1994	WO
WO 94/10202	May 1994	WO
WO 94/28017	December 1994	WO

OTHER PUBLICATIONS

Hagemeier et al. (1986) Int. J. Cancer 38:481-88.
Songsivilai et al. (1990). Clin. Exp. Immunol. 79:315-21.
Brennan et al. (1985). Science 229:81-83.
Morrissey et al. (1988). Thromb. Res. 52:247-61.
Campbell, A.M. (1986). Laboratory Techniques in Biochemistry and Molecular Biology, vol. 13, pp. 66-265.
Rettig et al. (1992). Proc. Natl. Acad Sci 89:10832-36.
Allowed Claims of U.S. Serial No. 08/327,709, Dvorak.
Osband and Ross, "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," Immunotherapy, 11:193-195, 1990.
Chatterjee, et al., "Idiotypic antibody immunotherapy of cancer," Cancer Immunol. Immunotherapy, 38:75-82, 1994.
Osborn, et al., "Leukocyte Adhesion to Endothelium in Inflammation," Cell, 62:3-6, 1990.
June et al., "Role of the CD28 Receptor in T-Cell Activation," Immunology Today, 11 (6):211-216, 1990.
Denekamp, "Vascular Attack as a Therapeutic Strategy for Cancer," Cancer and Metastasis Reviews, 9:267-282, 1990.
Scott et al., "Anti-CD3 Antibody Induces Rapid Expression of Cytokine Genes In Vivo," The Journal of Immunology, 145(7):2183-2188, 1990.
O'Connell and Edidin, "A Mouse Lymphoid Endothelial Cell Line Immortalized by Simian Simian Virus 40 Binds Lymphocytes and Retains Functional Characteristics of Normal Endothelial Cells," The Journal of Immunology, 144(2):521-525, 1990.
Ledbetter et al., "CD 28 Ligation in T-Cell Activation: Evidence for Two Signal Transduction," Abstract only, Blood, 75(7):1531-1539, 1990.
Watanabe et al., "Exogenous Expression of Mouse Interferon .gamma. cDNA in Mouse Neuroblastoma C1300 Cells Results in Reduced Tumorigenicity by Augmented Anti-Tumor Immunity," Proceedings of the National Academy of Scientists, 86:9456-9460, 1989.
Schutt et al., "Human Monocyte Activation Induced by an Anti-CD14 Monoclonal Antibody," Immunology Letters, 19:321-328, 1988.
Thorpe et al., "Improved Antitumor Effects of Immunotoxins Prepared with Deglycosylated Ricin A-Chain and Hindered Disulfide Linkages," Cancer Research, 48:6396-6403, 1988.
Glennie et al., "Preparation and Performance of Bispecific (F(ab'.gamma.).sub.2 Antibody Containing Thioether-Linked Fab'.gamma. Fragments," The Journal of Immunology, 139(7):2367-2375, 1987.
Bevilacqua et al., "Identification of an Inducible Endothelial-Leukocyte Adhesion Molecule," Proceedings of the National Academy of Scientists, 84:9238-9242, 1987.
Cotran et al., "Induction and Detection of a Human Endothelial Activation Antigen In In Vivo," Abstract only, The Journal of Experimental Medicine, 164(2):661-666, 1986. 1986.
Groenewegen et al. "Lymphokine Dependence of In Vivo Expression of MHC Class II

Antigens by Endothelium," Nature, 316:361-263, 1985.
Moretta et al., Abstract only, The Journal of Experimental Medicine, 162(3):823-838, 838, 1985.
Vaickus and Foon, "Overview of Monoclonal Antibodies in the Diagnosis and Therapy of of Cancer," Cancer Investigation, 93(2):295-209, 1991.
Hagemeier et al., "A Monoclonal Antibody Reacting with Endothelial Cells of Budding Vessels in Tumors and Inflammatory Tissues, and Non-Reactive with Normal Adult Tissues," International Journal of Cancer, 38:481-488, 1986.
Duijvestijn et al., "Lymphoid Tissue- and Inflammation-Specific Endothelial Cell Differentiation defined by Monoclonal Antibodies," The Journal of Immunology, 138 (3):713-719, 1987.
Murray et al., "Vascular Markers for Murine Tumours," Radiotherapy and Oncology, 16:221-234, 1989.
Schlingemann et al., "Monoclonal Antibody PAL-E Specific for Endothelium," Laboratory Investigation, 52(1):71-76, 1985.
Bruland et al., "New Monoclonal Antibodies Specific for Human Sarcomas," International Journal of Cancer, 38:27-31, 1986.
Reisfeld et al., "Human Tumor-Associated Antigens Defined by Monoclonal Antibodies," Antibodies," CRC Critical Reviews in Immunology, 5(1):27-53, 1984.
Schlom et al., "Monoclonal Antibodies Reactive with Breast Tumor-Associated Antigens," Advances in Cancer Research, 43:143-173, 1985.
Kaplan, "The Diagnostic and Therapeutic Use of Monoclonal Antibodies in Colorectal Cancer," Hematology/Oncology Clinics of North American, 3(1):125-134, 1989.
Smith and Teng, "Clinical Applications of Monoclonal Antibodies in Gynecologic Oncology," Cancer, 60:2068-2074, 1987.
Stavrou, "Monoclonal Antibodies in Neuro-Oncology," Neurosurgery Review, 13:7-18, 1990.
Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the Her2 Protooncogene to the Clinic," Journal of Clinical Immunology, 11(3):117-127, 1991.
Szymandera, "Clinical Usefulness of Three Monoclonal Antibody-Defined Tumor Markers: Markers: CA 19-9, CA 50, and CA 125," Tumour Biology, 7:333-342, 1986.
Catane and Longo, "Monoclonal Antibodies for Cancer Therapy," Israel Journal of Medical Sciences, 24:471-476, 1988.
Greiner et al., "Applications of Monoclonal Antibodies and Recombinant Cytokines for for the Treatment of Human Colorectal and Other Carcinomas," Journal of Surgical Oncology Supplement, 2:9-13, 1991.
Thor and Edgerton, "Monoclonal Antibodies Reactive with Human Breast or Ovarian Carcinoma: In Vivo Applications," Seminars in Nuclear Medicine, 19(4):295-308, 1989. 1989.
Thorpe et al., "Selective Killing of Proliferating Vascular Endothelial Cells by an Anti-Fibronectin Receptor Immunotoxin," 16th LH Gray Conference, Sep. 17-21, 1990.
Ghose et al., "Preparation of Antibody-Linked Cytotoxic Agents," Methods in Enzymology, 93:280-333, 1983.
Thorpe et al., "Targeting to proliferating vascular endothelium," Int. Symp. on Angio., Mar. 13-15, 1991.
Knowles and Thorpe, "Purification of Immunotoxins Containing Ricin A-Chain and Abrin Abrin A-Chain Using Blue Sepharose CL-6B," Analytical Biochemistry, 160:440-443, 1987.
Wang et al., "Photoreactive In-Cyclodextrin Inclusion Complex: a New Heterobifunctional Reagent for Antibody Labeling," Nuclear Medicine and Biology, 19 (8):897-902, 1992.
PCT Search Report mailed Jun. 25, 1993.
Alvarez et al., "Localization of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Human Glial Neoplasms," Modern Pathology, 5(3):303-307, 307, 1992.
Brown et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract," Cancer Research, 53:4727-4735, 1993.
Kim et al., "Inhibition of vascular endothelial growth factor-induced aniogenesis suppresses tumor growth in vivo," Nature, 362:841-843, 1993.

Dvorak et al., "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels," J. Exp. Med., 174:1275-1278, 1991.
Gerlach et al., "Enhanced Responsiveness of Endothelium in the Growing/Motile State to Tumor Necrosis Factor/Cachectin," J. Exp. Med., 170:913-931, 1989.
Gougos et al., "Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts," International Immunology, 4(1):83-92, 1991.
Gougos et al., "Identification of a Human Endothelial Cell Antigen with Monoclonal Antibody 44G4 Produced Against a Pre-B Leukemic Cell Line," The Journal of Immunology, 141:1925-1933, 1988.
Gougos et al., "Biochemical Characterization of the 44G4 Antigen from the Hoon Pre-B B Leukemic Cell Line," The Journal of Immunology, 141:1934-1940, 1988.
Hagemeier et al., "A Monoclonal Antibody Reacting with Endothelial Cells of Budding Vessels in Tumors and Inflammatory Tissues, and Non-Reactive with Normal Adult Tissues," Int. J. Cancer, 38:481-488, 1986.
Jakeman et al., "Binding Sites for Vascular Endothelial Growth Factor Are Localized on Endothelial Cells in Adult Rat Tissues," J. Clin. Invest., 89:244-253, 1992.
Nabel et al., "Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo," Nature, 362:844, 1993.
O'Connell et al., "Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule," Clin. Exp. Immunol., 90:154-159, 1992.
Plate et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," Cancer Research, 53 (23):5822-5827, 1993.
Plate et al., "Vascular endothelial growth factor is a potential tumour angiogenesis angiogenesis factor in human gliomas in vivo," Nature, 359:845-848, 1992.
Rettig et al., "Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer," Proc. Natl. Acad. Sci. USA, 89:10832-10836, 1992.
Sarma et al., "Cloning of a Novel Tumor Necrosis Factor-.alpha.-Inducible Primary Response Gene that is Differentially Expressed in Development and Capillary Tube-Like Formation in vitro," The Journal of Immunology, 148:3302-3312, 1992.
Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," Cancer and Metatasts Reviews, 12:303-324, 1993.
Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature, 359:843-845, 1992.
Wang et al., "A Monoclonal Antibody Detects Heterogeneity in Vascular Endothelium of of Tumours and Normal Tissues," Int. J. Cancer, 54:363-370, 1993.
Westphal et al., "A New 180-kDa Dermal Endothelial Cell Activation Antigen: In Vitro Vitro and In Situ Characteristics," The Journal of Investigative Dermatology, 100 (1):27-34, 1993.
Yeo et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Guinea Pig and Human Tumor and Inflammatory Effusions," Cancer Research, 53:2912-2918, 1993.
Buring et al., "Endoglin is expressed on a subpopulation of immature erythroid cells cells of normal human bone marrow," Leukemia, 5(10):841-847, 1991.
Dvorak et al., "Structure of Solid Tumors and Their Vasculature: Implications for Therapy with Monoclonal Antibodies," Cancer Cells, 3(3):77-85, 1991.
Gougos and Letarte, "Primary Structure of Endoglin, an RGD-containing Glycoprotein of Human Endothelial Cells," The Journal of Biological Chemistry, 265(15):8361-8364, 8364, 1990.
Bach et al., "Factor VII Binding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperatively by Phosphatidylserine," Biochemistry, 25:4007-4020, 1986.
Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin GI Fragments," Science, 229:83-83, 1985.
Bruland et al., "Expression and Characterisitics of a Novel Human Osteosarcoma-associated Cell Surface Antigen," Cancer Res., 48:5302, 1983.
Burrows and Thorpe, "Eradication of Large Solid Tumors in Mice With an Immunotoxin

Directed Against Tumor Vasculature," Proc. Natl. Acad. Sci (USA), 90:8996-9600, 1993.
Burrows et al., "A Murine Model for Antibody-Directed Targeting of Vascular Endothelial cells in solid tumors," Cancer Res., 52:5954-5962, 1992.
Burrows et al., "Influence of Tumor-derived Interleukin-1 on Melanoma-endothelial Cell Interactions in Vitro," Cancer Res., 51:4768-4775, 1991.
Carnemolla et al., "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," J. Cell. Biol., 108:1139, 1989.
Carnemolla et al., "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications That Unmask a Cryptic Sequence," Journal of Biological Chemistry, 267(34):24689-24692, 1992.
Denekamp and Hobson, "Endothelial Cell Proliferation in Experimental Tumours." Brit. Brit. J. Cancer, 461:711-720, 1982.
Dewerchin et al., "Effect of Chemical Conjugation of Recombinant Single-Chain Urokinase-Type Plasminogen Activator With Monoclonal Antiplatelet Antibodies on Platelet Aggregation and on Plasma Clot Lysis In Vitro and In Vivo," Blood, 78 (4):1005-1018, 1991.
Edgington et al., "The Structural Biology of Expression and Function of Tissue Factor," Thrombosis and Haemostasis, 66(1):67-79, 1991.
Epenetos et al., "Limitations of Radiolabeled Monoclonal Antibodies for Localization Localization of Human Neoplasms," Cancer Res., 46:3183-3191, 1986.
Fiore et al., "The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa," J. Biol. Chem., 269:143-149, 1994.
Fisher et al., "Cloning and Expression of Human Tissue Factor cDNA," Thrombosis Research, 48:89-99, 1987.
Folkman, Tumor Angiogenesis, Adv. Cancer Res., 43:175-230, 1985.
Frelinger et al., "Monoclonal Antibodies to Ligand-occupied Conformers of Integrin .alpha..sub.IIb .beta..sub.3 (Glycoprotein IIb-IIIa) Alter Receptor Affinity, Specificity, and Function," Journal of Biological Chemistry, 266 (26):17106-17111, 1991.
Frelinger et al., "Selective Inhibition of Integrin Function by Antibodies Specific for Ligand-occupied Receptor Conformers," Journal of Biological Chemistry, 265 (11):6346-6352, 1990.
Hayward et al., "p-155, a Multimeric Platelet Protein That Is Expressed on Activated Activated Platelets," Journal of Biological Chemistry, 266(11):7114-7120, 1991.
Heynen et al., "Absence of Ligands Bound to Glycoprotein IIB-IIIA on the Exposed Surface of a Thrombus May Limit Thrombus Growth in Flowing Blood," J. Clin. Invest., Invest., 94:1098-1112, 1994.
Jain, Vascular and Interstitial Barriers to Delivery of Therapeutic Agents in Tumors. Cancer Meta. Rev., 9(3):253-266, 1990.
Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies," Growth Factors, 7:53-64, 1992.
Kondo et al., "Significance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and Its Inhibition by the Antibody," Biochemical and Biophysical Research Communications, 194(3):1234-1241, 1993.
Krishnaswamy et al., "Role of the Membrane Surface in the Activation of Human Coagulation Factor X," J. Biol. Chem., 267:26110-26120, 1992.
Martin et al., "Tissue factor: Molecular recognition and cofactor function," FASEB J., 9:852-859, 1995.
Morrissey et al., "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade," Cell, 50:129-135, 1987.
Morrissey et al., "Monoclonal Antibody Analysis of Purified and Cell-Associated Tissue Factor," Thrombosis Research, 52:247-261, 1988.
Morrissey et al., "Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation," Blood, 81:734-744, 1993.
Murray et al., "Tumor-derived Factors Which Induce Endothelial Tissue Factor and

Enhance the Procoagulant Response to TNF," Intl. J. Rad. Biology, 60:273-277, 1991.

Nawroth et al., "Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas," J. Exp. Med., 168:637-647, 1988.
Nemerson, "Tissue Factor and Hemostasis," Blood, 71(1):1-8, 1988.
Neuenschwander and Morrissey, "Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIaGla domain is dispensable for binding to tissue factor but important for activation of factor X," J. Biol. Chem., 269:8007-8013, 1994.
Paborsky et al., "Lipid Association, but Not the Transmembrane Domain, Is Required for Tissue Factor Activity," J. Biol. Chem., 266:21911-16, 1991.
Paborsky et al., "Purification of Recombinant Human Tissue Factor," American Chemical Society, 1989.
Rehemtulla et al., "High Level Expression of Recombinant Human Tissue Factor in Chinese Hamster Ovary Cells as a Human Thromboplastin," Thrombosis and Haemostasis, 65(5):521-527, 1991.
Rucco et al., "Cytokine Production (IL-a alpha, IL-1 beta, and TNF alpha) and Endothelial Cell Activation (ELAM-1 and HLA-DR) in Reactive Lymphadenits, Hodgkin's Disease, and in Non-Hodgkin's Lymphomas," Am. J. Pathol., 137(5):1163-1171, 1990.
Ruf and Edgington, "An Anti-Tissue Factor Monoclonal Antibody Which Inhibits TF-VIIa VIIa Complex is a Potent Anticoagulant in Plasma," Thrombosis and Haemostasis, 66 (5):529-533, 1991.
Ruf and Edgington, "Structural biology of tissue factor, the initiator of thrombogenesis in vivo," The FASEB Journal, 8:385-390, 1994.
Ruf and Edgington, "Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor VIIa," Proc. Natl. Acad. Sci. USA, 88:8430-8434, 1991.
Ruf et al., "Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function," Journal of Biological Chemistry, 266 (4):2158-2166, 1991.
Ruf et al., "Tissue Factor Residues 157-167 are Required for Efficient Proteolytic Activation of Factor X and Factor VII," Journal of Biological Chemistry, 267 (31):22206-22210, 1992.
Scarpati et al., "Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene," Biochemistry, 26:5234-5238, 1987.
Schlingemann et al., "Leukocyte Antigen CD34 is Expressed by a Subset of Cultured Endothelial Cells and on Endothelial Albminal Microprocesses in the Tumor Stroma," Laboratory Investigation, 62:690-696, 1990.
Sioussat et al., "Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies," Archives of Biochemistry and Biophysics, 301(1):15-20, 1993.
Spicer et al., "Isolation of cDNA clones coding for human tissue factor: Primary structure of the protein and cDNA," Proc. Natl. Acad. Sci. USA, 84:5148-5152, 1987.

ten Cate et al., "The activation of factor X and prothrombin by recombinant factor VIIa is mediated by tissue factor," J. Clin. Invest., 92:1207-1212, 1993.
Thieme et al., "Comparative Analysis of Vascular Endothelial Growth Factor Receptors Receptors on Retinal and Aortic Vascular Endothelial Cells," Diabetes, 44:98, 1995.

Tomiyama et al., "The Arg-Gly-Asp (RGD) Recognition Site of Platelet Glycoprotein IIB-IIIa on Nonactivated Platelets is Accessible to High-Affinity Macromolecules," Blood, 79(9):2302-2312, 1992.
Ugarova et al., "Conformational Changes in Fibrinogen Elicited by its Interaction with Platelet Membrane Glycoprotein GPIIb-IIIa," Journal of Biological Chemistry, 268(28):21080-21087, 1993.
Zacharski et al., "Tumor Cell Procoagulant and Urokinase Expression in Carcinoma of the Ovary," J. Natl. Cancer Inst., 85:1225-1230, 1993.
Zamarron et al., "A Receptor-induced Binding Site in Fibrinogen Elicited by its Interaction with Platelet Membrane Glycoprotein IIb-IIIa," Journal of Biological Chemistry, 266(24)16193-16199, 1991.

UTSD:419; Serial No. 08/273,567, filed Jul. 11, 1994; C.I.P. of UTSD:419.
UTSD:456; Serial No. 08/485,482, filed Jun. 7, 1995; C.I.P. of UTSD:419.
UTSD:457; Serial No. 08/487,427, filed Jun. 7, 1995; C.I.P. of UTSD:419.
UTSD:459; Serial No. 08/479,733, filed Jun. 7, 1995; C.I.P. of UTSD:419.
UTSD:460; Serial No. 08/472,631, filed Jun. 7, 1995; C.I.P. of UTSD:419.
UTSD:461; Serial No. 08/479,727, filed Jun. 7, 1995; C.I.P. of UTSD:419.
UTSD:462; Serial No. 08/481,904, filed Jun. 7, 1995; C.I.P. of UTSD:419.
Burrows and Thorpe, "Targeting the Vasculature of Solid Tumors," Journal of Controlled Release, 28:195-202, Jan. 1994.
Clauss et al., "A Polypeptide Factor Produced by Fibrosarcoma Cells That Induces Endothelial Tissue Factor And Enhances the Procoagulant Response to Tumor Necrosis Factor/Cachetin," The Journal of Biological Chemistry, 265(12):7078-7083, Apr. 1990. 1990.
Thorpe and Burrows, "Antibody-Directed Targeting of the Vasculature of Solid Tumors," Breast Cancer Research and Treatment, 36(2):237-251, 1995.
Yamazaki et al., "Bispecific Monoclonal Antibodies with Specificities for Activated Platelets and Thrombolytic Agents, Their Production and Use," Abstract for Canadian Patent Application CA 2039259; Chem Abstracts, 117(11), Abstract #109988.
International Search Report, Mailed Nov. 24, 1995.
Burgess et al., "Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Receptor-Biding Activities by Site-Directed Mutagenesis of a Single Lysine Residue," Residue," J. Cell Biol., 111:2129-2138, 1990.
Gillies and Wesolowski, "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities," Hum. Antibod. Hybridomas, 1(1):47-54, 1990.
Lapierre et al., "Three Distinct Classes of Regulatory Cytokines Control Endothelial Endothelial Cell MHC Antigen Expression," J. Exp. Med., 167:794-804, 1988.
Lazar et al., "Transforming Growth Factor .alpha.: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Mol. Cell Biol., 8(3):1247-1252, 1988.
Qian et al. , "Human Peripheral Blood Lymphocytes Targeted with Bispecific Antibodies Release Cytokines That Are Essential for Inhibiting Tumor Growth," J. Immunol., 146(9):3250-3256, 1991.
Tao and Morrison, "Studies of Aglycosylated Chimeric Mouse-Human IgG--Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," J. Immunol., 143(8):2595-2601, 1989.
Waldman, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," Science, 252: 1657-1662, 1991.
Wen et al., "Effect of .gamma.-Interferon on Major Histocompatibility Complex Antigen Expression and Lymphocytic Infiltration in the 9L Gliosarcoma Brain Tumor Model: Implications for Strategies of Immunotherapy," J. Neuroimmunol., 36:57-68, 1992.
Aoyagi, "Distribution of Plasma Fibronectin in the Metastatic Lesion of Cancer: Experimental Study by Autoradiography," Thrombosis Research, 49:265-75, 1988.
Balza et al., "Production and Characterization of Monoclonal Antibodies Specific for for Different Epitopes of Human Tenascin," FEBS 332(1,2):39-43, 1993.
Bjorndahl, et al., "Human T Cell Activation: Differential Response to Anti-CD28 As Compared to Anti-CD3 Monoclonal Antibodies," Eur. J. Immunol., 19:881-87, 1989.
Blanchard, et al., "Infiltration of Interleukin-2-Inducible Killer Cells in Ascitic Fluid and Pleural Effusions of Advanced Cancer Patients," Cancer Research, 48:6321-27, 1988.
Bohlen, et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies," Cancer Research, 53:4310-14, 1993.
Borsi, et al., "Expression of Different Tenascin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 52:688-92, 1992.
Boyer, et al., "Differential Induction by Interferons of Major Histocompatibility Complex-Encoded and Non-Major Histocompatibility Complex-Encoded Antigens in Human Breast and Ovarian Carcinoma Cell Lines," Cancer Research, 49:2928-34, 1989.
Burton-Wurster, et al., "Expression of the Ed B Fibronectin Isoform in Adult Human

Articular Cartilage," Biochemical and Biophysical Research Communication 165(2): 782-87, 1989.
Collins, et al., "Immune Interferon Activates Multiple Class II Major Histocompatibility Complex Genes and the Associated Invariant Chain Gene in Human Endothelial Cells and Dermal Fibroblasts," Proc. Natl. Acad. Sci. USA, 81:4917-21, 1984.
Carnemolla et al., "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," The Journal of Cell Biology, 108:1139-48, 1989.
Carnemolla et al., "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications that Unmask a Cryptic Sequence," The The Journal of Biological Chemistry, 267(34):24589:92, 1992.
Carnemolla, et al., "Phage Antibodies with Pan-Species Recognition of the Oncofoetal Oncofoetal Angiogenesis Marker Fibronectin ED-B Domain," Int. J. Cancer 63:397-405, 1996.
Castellani, et al., "The Fibronectin Isoform Containing the ED-B Oncofoetal Domain: A Marker of Angiogenesis," Int. J. Cancer, 59:612-18, 1994.
Conforti, et al., "Human Endothelial Cells Express Integrin Receptors on the Luminal Luminal Aspect of Their Membrane," Blood 80(2):437-46, 1992.
Dillman, "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, 111(7) 592-600, 1989.
Farnoud, et al., "Fibronectin Isoforms Are Differentially Expressed in Normal and Adenomatous Human Anterior Pituitaries," Int. J. Cancer, 61:27-34, 1995.
Garin-Chesa, et al., "Cell Surface Glycoprotein of Reactive Stromal Fibroblasts As A A Potential Antibody Target in Human Epithelial Cancers," Proc. Natl. Acad. Sci. USA, 87:7235-39, 1990.
Groenewegen, et al., "Lymphokine Dependence of In Vivo Expression of MHC Class II Antigens by Endothelium," Nature, 316:361-63, 1985.
Harris and Emery, "Therapeutic Antibodies--The Coming of Age," Btech, 11:42-44, 1993.
June, et al., "T-Call Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression," Molecular and Cellular Biology 7(12):4473-81, 1987.
Kaczmarek, et al., "Distribution of Oncofetal Fibronectin Isoforms in Normal Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 58:11-16, 1994.
Koulova et al., "The CD28 Ligand B7/BB1 Provides Costimulatory Signal for Alloactivation of CD4+ T Cells," J. Exp. Med. 173:759-62, 1991.
Kurosawa, et al., "Early Appearance and Activation of Natural Killer Cells in Tumor-Tumor-Infiltrating Lymphoid Cells During Tumor Development," Eur. J. Immunol. 23:1029-33, 1993.
Lampugnani, et al., "The Role of Integrins in the Maintenance of Endothelial Monolayer Integrity," The Journal of Cell Biology, 112(3):479-90, 1991.
Linnala, et al., "Human Amnion Epithelial Cells Assemble Tenascins and Three Fibronectin Isoforms in the Extracellular Matrix," FEBS, 314(1,2):74-78, 1993.
Maeda, et al., "Production and Characteriztion of Tumor Infiltrating Lymphocyte Clones Derived from B16-F10 Murine Melanoma," The Journal of Investigative Dermatology 97(2):183-89, 1991.
Natali, et al., "Comparative Analysis of the Expression of the Extracellular Matrix Protein Tenascin in Normal Human Fetal, Adult and Tumor Tissues," Int. J. Cancer, 47:811-16, 1991.
Oyama, et al., "Coordinate Oncodevelopmental Modulation of Alternative Splicing of Fibronectin Pre-Messenger RNA at ED-A, ED-B and CS1 Regions in Human Liver Tumors," Cancer Research 53:2005-11, 1993.
Peters, et al., "Expression of the Alternatively Spliced EIIIB Segment of Fibornectin," Cell Adhesion and Communication, 3:67-89, 1995.
Pober et al., "Ia Expression by Vascular Endothelium Is Indcuible by Activated T Cells and by Human .gamma. Interferon," J. Exp. Med. 157: 1339-53, 1983.
Pohl, et al., "CD30-Antigen-Specific Targeting and Activation of T Cells via Murine Bispecific Monoclonal Antiodies Against CD3 and CD28: Potential Use for the Treatment of Hodgkin's Lymphoma," Int. J. Cancer, 54:820-27, 1993.

Renner, et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells," Science, 264:833-35, 1994.
Rettig, et al., "Cell-Surface Glycoproteins of Human Sarcomas: Differential Expression in Normal and Malignant Tissues and Cultured Cells," Proc. Natl. Acad. Sci. USA, 85:3110-14, 1988.
Rettig, et al., Identification of Endosialin, A Cell Surface Glycoprotein of Vascular Endothelial Cells in Human Cancer, Proc. Natl. Acad. Sci. USA, 89:10832-36, 36, 1992.
Rosenberg, Steven, "Lymphokine-Activated Killer Cells: A New Approach to Immunotherapy of Cancer," JNCI 75(4):595-603, 1985.
Rosenberg, et al., "Observations of the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastic Cancer," The New England Journal of Medicine, 313(23):1485-92, 1985.
Ruiter, et al., "Monoclonal Antibody-Defined Human Endothelial Antigens as Vascular Markers," J. Investigative Dermatol., 93(2):25S-32S, 1989.
Saiki et al., "Anti-metastatic and Anti-invasive Effects of Polymeric Arg-Gly-Asp (RGD) Peptide, Poly(RGD), and Its Analogues," Jpn. J. Cancer Res. 81:660-67, 1990.
Saiki et al., "Inhibition of Tumor Angiogenesis by a Synthetic Cell-Adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD)," Jpn. J. Cancer Res. 81:668-75, 1990.
Schlingemann, et al., "Differential Expression of Markers for Endothelial Cells, Pericytes, and Basal Lamina in the Microvasculature of Tumors and Granulation Tissue," Am. J. Pathol., 138(6):1335-47, 1991.
Schwarzbauer, "Alternative Splicing of Fibronectin: Three Variants, Three Functions," BioEssays 13(10)527-33, 1991.
Siri, et al., "Human Tenascin: Primary Structure, Pre-mRNA Splicing Patterns and Localization of the Epitopes Recognized by Two Monoclonal Antibodies," Nucleic Acids Acids Research, 19(3):525-31, 1991.
Steiniger, et al. "Inteferon-.gamma. in Vivo. Induction and Loss of Class II MHC Antigens and Immture Myelomonocytic Cells in Rat Organs," Eur. J. Immunol. 18:661-69, 1988.
Street, et al., "In Vivo Administration of Fab' Fragments of Anti-L3T4 (GK1.5) Antibody Inhibits the T Helper Cell Function of Murine Lymph Node Cells," Cellular Immunology 120:75-81, 1989.
Thompson, et al., "CD28 Activation Pathway Regulates the Production of Multiple T-Cell-Derived Lymphokines/Cytokines," Proc. Natl. Acad. Sci. USA, 86:1333-37, 1989.
Ueda, et al., "Selective Distribution of Fibronectin to a Tumor-Cell Line," Cancer Letters 31:261-65, 1986.
Vartio, et al., "Differential Expression of the ED Sequence-Containing Form of Cellular Fibronectin in Embryonic and Adult Human Tissues," Journal of Cell Science, Science, 88:419-30, 1987.
Welt, et al., "Phase I Localization Study of .sup.131 I-monoclonal Antibody F19 Detecting an Activation Antigen of Neoplastic Stroma," Proceedings of the American Association for Cancer Research, 33:319, 1992, Abstract No. 1900.
Werb, et al., "Signal Transduction through the Fibronectin Receptor Induces Collagenase and Stromelysin Gene Expression," The Journal of Cell Biology, 109:877-89, 1989.
European Application Serial No. 93 906 289.9 Office Action dated Sep. 25, 1997.
European Application Serial No. 93 923 817.1 Office Action dated Sep. 25, 1997.
Willicome et al., A Monoclonal Antibody That Detects A Novel Antigen On Endothelial Cells That Is Induced By Tumor Necrosis Factor, IL-1, Or Lipopolysaccharide, J. Immunol., 144(7):2558-2565, Apr. 1, 1990.
Dermer, "Another Anniversary for the War on Cancer", Bio/technology, 12, 320 (1994). (1994).
Pober and Cotran, "What Can Be Learned From the Expression of Endothelial Adhesion Molecules in Tissues?", Laboratory Investigation, 64(3), 301-305 (1991).

ART-UNIT: 162

PRIMARY-EXAMINER: Feisee; Lila

ASSISTANT-EXAMINER: Bansal; Geetha P.

ATTY-AGENT-FIRM: Arnold, White & Durkee, P.C.

ABSTRACT:

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

103 Claims, 11 Drawing figures

First Hit Fwd Refs

L19: Entry 20 of 39 File: USPT Dec 28, 1999

DOCUMENT-IDENTIFIER: US 6008319 A
TITLE: Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof

CLAIMS:

1. An isolated and purified vasoactive peptide, said peptide comprising a fragment of interleukin-2 containing amino acids 37 to 58 of SEQ ID NO: 3, wherein said fragment and said peptide are substantially free of cytokine activity, and enhance vascular permeability when localized at a target site.

2. A dimer of the vasoactive peptide of claim 1.

3. The peptide of claim 1 consisting of residues 37 to 58 of amino acid sequence SEQ SEQ ID NO: 3.

4. The peptide of claim 1 consisting of amino acid sequence SEQ ID NO: 1.

5. The dimer of claim 2, wherein each peptide of the dimer includes at least one cysteine residue, wherein the cysteine residues form the dimer by a disulfide bridge.

6. A conjugate comprising:

a) a delivery vehicle that localizes at the site of neoplastic tissue; and

b) the vasoactive peptide of claim 1, said peptide being connected to said delivery vehicle.

7. The conjugate of claim 6, wherein the delivery vehicle is a tumor specific monoclonal antibody.

8. The conjugate of claim 7, wherein the monoclonal antibody is selected from the group consisting of a murine antibody, a human antibody, and a chimera of human and murine antibodies.

11. The conjugate of claim 7, wherein the monoclonal antibody is an antibody to HLA-DR antigen, nuclear histone H1, or fibronectin.

12. A fusion protein comprising:

a) a delivery vehicle that localizes at the site of neoplastic tissue, the vehicle having at least one terminal amino acid; and

b) at least one vasoactive peptide according to claim 1, the peptide being joined to to at least one terminal amino acid of the delivery vehicle.

13. The fusion protein of claim 12 further comprising an amino acid linker joining the delivery vehicle and the vasoactive peptide.

14. The fusion protein of claim 12, wherein the at least one vasoactive peptide

comprises two tandemly linked vasoactive peptides.

15. The fusion protein of claim 14 further comprising an amino acid spacer between the two tandemly linked vasoactive peptides.

16. The fusion protein of claim 12, wherein the delivery vehicle comprises at least one antigen binding domain of an immunoglobulin.

17. The fusion protein of claim 12, wherein the delivery vehicle comprises a human-mouse chimeric monoclonal antibody.

18. A vector for the expression of fusion protein, comprising:

a) a fusion protein sequence comprising;

1) a delivery vehicle encoding sequence, wherein said delivery vehicle localizes at the site of neoplastic tissue, and

2) a vasoactive peptide encoding sequence, comprising DNA encoding the vasoactive peptide of claim 1, said peptide encoding sequence having a reading frame aligned with the reading frame of said delivery vehicle encoding sequence; and

b) an expression vector having at least one sequence that directs expression of the fusion protein sequence in cells.

20. A therapeutic kit, comprising:

a) a conjugate, said conjugate comprising:

1) a delivery vehicle that localizes at the site of neoplastic tissue, and

2) the vasoactive peptide of claim 1, said peptide being connected to said delivery vehicle; and

b) an antineoplastic therapeutic agent.

21. A diagnostic kit, comprising:

a) a conjugate, said conjugate comprising:

1) a delivery vehicle that localizes at the site of neoplastic tissue, and

2) the vasoactive peptide of claim 1, said peptide being connected to said delivery vehicle; and

b) a tumor imaging agent.

22. An isolated and purified vasoactive peptide, said peptide consisting of a portion of SEQ ID NO: 3 from amino acid residues 22 to 72containing amino acid residues 37 to 58 of SEQ ID NO: 3, said portion being 22 to 51 amino acids in length.

23. The peptide of claim 22, wherein the portion of SEQ ID NO: 3 is selected from the group consisting of:

a) amino acid residues 37 to 58:

b) amino acid residues 33 to 58;

c) amino acid residues 22-58; and

d) amino acid residues 37-72.

First Hit Fwd Refs

L19: Entry 37 of 39 File: USPT May 30, 1995

DOCUMENT-IDENTIFIER: US 5420012 A
** See image for Certificate of Correction **
TITLE: Method for the detection of reactive conditions

CLAIMS:

1. A method for screening for the presence of a malignant tumor in a patient, comprising:

a) determining the concentration of at least one of extra domain A-containing cellular fibronectin and its extra domain A sequence in a sample of plasma or serum from the patient by an immunoreaction with an antibody that specifically binds to the extra domain A sequence indicative of said malignant tumor; and

b) comparing the determined concentration with an average concentration of extra domain A-containing cellular fibronectin or its extra domain A sequence in healthy patients, at least a twofold increase of extra domain A-containing cellular fibronectin or its extra domain A sequence in said sample of said patient, as compared to healthy blood donors, indicating the possible presence of said malignant tumor.

2. A method as claimed in claim 1, wherein the tumor is a carcinoma.

First Hit Fwd Refs

End of Result Set

L19: Entry 39 of 39 File: USPT Jan 16, 1990

DOCUMENT-IDENTIFIER: US 4894326 A
TITLE: Monoclonal antibody defining oncofetal structure of fibronectin

CLAIMS:

1. An immunological binding partner defined by specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.

2. A test kit useful for assaying the presence of oncofetal fibronectin, comprising one or more containers containing the immunological binding partner of claim 1.

6. A method of immunological detection of cells expressing oncofetal fibronectin comprising the steps of reacting biopsied cells with the composition of claim 4 and detecting detectable marker coupled to reacted immunological binding partner on the cells.

8. The method of claim 6 wherein the cells are tumor cells.

11. A hybridoma cell line capable of producing a monoclonal antibody capable of specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.

12. Hybridoma cell line ATCC No. HB9018 according to claim 11.

13. A monoclonal antibody produced by the hybridoma a cell line of claim 11.

14. The monoclonal antibody of claim 13 coupled to a radionuclide.

15. In a method of detecting tumor-associated antigen in blood serum including the steps of contacting the serium with antibody directed to tumor-associated antigen and detecting any reaction between the antibody and serum antigen, the improvement comprising contacting the serum with the antibody of claim 13.

16. A test kit useful for assaying the presence of oncofetal fibronectin, comprising one or more containers containing the monoclonal antibody of claim 13.